Add BrightSurf on Google Email

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer

Patients with BRAF V600E mutations showed a 60.9% overall response rate to a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy, compared to 40% with standard-of-care treatment. This triple-combination therapy offers an effective new first-line treatment option for patients with this mutation.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateJan 25, 2025

U of M Medical School study highlights financial burden of medical equipment on cancer survivors

A University of Minnesota Medical School study reveals that medical equipment is the leading cause of out-of-pocket costs for cancer patients, with wheelchairs and hearing aids among the most expensive items. The research emphasizes the need to address accessibility and affordability issues to improve cancer survivor care.

SourceUniversity of Minnesota Medical School·JournalJAMA Network Open·TypeData/statistical analysis·DateJan 23, 2025

RSClin® Tool N+ gives more accurate estimates of recurrence risk and individual chemotherapy benefit in node-positive breast cancer

The RSClin Tool N+ provides more accurate estimates of recurrence risk and individual chemotherapy benefit in node-positive breast cancer. The tool combines clinical and pathologic factors with the 21-gene Oncotype DX Breast Recurrence Score to predict patient-level prognosis and treatment benefit.

SourceSWOG Cancer Research Network·JournalJournal of Clinical Oncology·TypeData/statistical analysis·DateJan 23, 2025

New biomarkers to detect colorectal cancer

Researchers at University of Birmingham have discovered three new protein biomarkers TFF3, LCN2, and CEACAM5 that show strong predictive potential for colorectal cancer. These biomarkers are linked to cell adhesion and inflammation, processes closely associated with cancer development.

SourceUniversity of Birmingham·JournalFrontiers in Oncology·TypeData/statistical analysis·DateJan 20, 2025

Prognostic power of the micropapillary pattern in pancreatic ductal adenocarcinoma: A game changer

Researchers studied the prognostic power of micropapillary patterns in PDAC, finding that even small percentages serve as independent prognostic factors for decreased survival. The study suggests incorporating micropapillary pattern percentage into pathology reports could enhance patient management strategies.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Pathology·DateJan 20, 2025

UTHealth Houston research: Children born to young men with cancer have slight increases in preterm birth, low-birth-weight children, but not birth defects

According to UTHealth Houston research, adolescent and young adult men with cancer have a slightly elevated risk of having preterm birth and children with low birth weight. However, the likelihood of live birth was highest for fathers who had thyroid cancer and lowest for those with gastrointestinal cancer.

SourceUniversity of Texas Health Science Center at Houston·JournalJNCI Journal of the National Cancer Institute·TypeData/statistical analysis·DateJan 16, 2025

U of A Cancer Center clinical trial advances research in treatment of biliary tract cancers

The study, published in the Journal of Clinical Oncology, showed no significant difference in patient survival between two-drug and three-drug chemotherapy regimens. The researchers found that the three-drug regimen may increase toxicity but could be a viable option for specific patients with certain types of biliary tract cancers.

SourceUniversity of Arizona Health Sciences·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateJan 16, 2025

Trastuzumab emtansine improves long-term survival in HER2 breast cancer

The phase 3 KATHERINE clinical trial found trastuzumab emtansine to be an effective adjuvant treatment for high-risk HER2-positive breast cancer patients, reducing the risk of death or invasive disease by 46% and improving survival. The study showed consistent benefits across patient subgroups, supporting T-DM1 as a new standard of care.

SourceUniversity of Pittsburgh·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJan 15, 2025

MRI scanning and biopsy could reduce delays in the correct treatment for bladder cancer by more than six weeks

A new trial has found that patients with suspected invasive bladder cancer treated with initial MRI imaging and biopsy are faster than those assessed with TURBT alone. The BladderPath trial showed a median time of 53 days from referral to correct treatment, compared to 98 days for usual care.

SourceUniversity of Birmingham·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateJan 15, 2025

Monitoring tumor-informed circulating tumor DNA after CGP

Researchers developed a system to monitor tumor-informed circulating tumor DNA (ctDNA) after comprehensive genomic profiling (CGP), enabling accurate prediction of patient outcomes. The study showed that this approach can be effectively used in conjunction with CGP data to predict cancer relapse and treatment response, improving person...

SourceTohoku University·JournalCancer Science·DateJan 15, 2025

NCCN joins international meeting to improve cancer care in the Middle East and North Africa region

The National Comprehensive Cancer Network (NCCN) has joined a two-day meeting in Riyadh, Saudi Arabia, to review updated NCCN Clinical Practice Guidelines for the MENA region. The guidelines provide evidence-based expert consensus-driven recommendations for cancer prevention, screening, treatment, and supportive care, tailored for uniq...

Researchers shed light on how to predict which skin cancer patients are most likely to respond to immunotherapy

A new study has identified macrophage activity as a key predictor of which skin cancer patients are most likely to respond to immunotherapy. The findings aim to improve personalized medicine for cancer patients and enable clinicians to select effective treatments, reducing side effects and costs.

SourceUniversity of Bath·JournalJCO Oncology Advances·TypeExperimental study·DateJan 8, 2025

University of Cincinnati Cancer Center study identifies potential new target to overcome breast cancer resistance

A University of Cincinnati Cancer Center study identifies microRNA miR-205 as a promising new target to overcome breast cancer treatment resistance and improve outcomes. The research found that boosting levels of miR-205 could block the production of MED1, a protein responsible for treatment resistance, and improve treatment outcomes.

SourceUniversity of Cincinnati·JournalCancers·DateJan 7, 2025

Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases

A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...

Psychedelic drug therapy may address mental health concerns in people with cancer and addiction

Two studies suggest that psilocybin-assisted psychotherapy can improve mental health outcomes for patients with cancer and alcohol use disorder, reducing symptoms of anxiety, depression, and obsessive thoughts, while also promoting lasting personality changes.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalAmerican Journal of Psychiatry·TypeRandomized controlled/clinical trial·DateJan 2, 2025

AI can improve ovarian cancer diagnoses

A new study published in Nature Medicine shows that AI-based models can accurately identify ovarian cancer in ultrasound images, achieving an accuracy rate of 86.3%. The models also reduce the need for expert referrals and misdiagnosis rates by 63% and 18%, respectively.

SourceKarolinska Institutet·JournalNature Medicine·DateJan 2, 2025

A speckle of hope for cancer patients

A new study by Katherine Alexander and Shelley Berger has found a possible source of variability in cancer treatment response in clear cell renal cell carcinoma (ccRCC). The researchers identified two distinct patterns of nuclear speckles in kidney tumors, which may correlate with patient outcomes.

SourceCold Spring Harbor Laboratory·JournalNature Cell Biology·DateJan 2, 2025

NRG Oncology study suggests the addition of SBRT to systemic therapy improves outcomes for select patients with locally advanced hepatocellular carcinoma

A Phase III clinical trial found that stereotactic body radiotherapy (SBRT) added to sorafenib improved progression-free survival and overall survival in patients with locally advanced hepatocellular carcinoma, particularly those with macrovascular invasion. The study also showed improvements in quality of life for these patients.

SourceNRG Oncology·JournalJAMA Oncology·DateDec 19, 2024

Children’s Hospital Colorado research transforms the standard of care for childhood cancer

The new therapy significantly improves three-year disease-free survival for children with B-ALL, with 96% being disease-free for at least three years. Blinatumomab is now being used in most patients due to its practice-changing breakthrough, offering improved quality of life and reduced side effects.

SourceChildren's Hospital Colorado·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateDec 18, 2024

Breakthrough in treatment approach showing promise in the fight against glioblastoma, the deadliest and most aggressive type of brain cancer

A phase 2 study conducted by Mayo Clinic found that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. The treatment, which combines short-course hypofractionated proton beam therapy with advanced imaging techniques, was more effective in patients over 65 with favorable tumor genetics.

SourceMayo Clinic·JournalThe Lancet Oncology·DateDec 16, 2024

Reiki therapy demonstrates significant symptom relief for cancer patients receiving infusion treatments

A study published in Journal of Pain and Symptom Management found that Reiki therapy resulted in clinically significant improvements in pain, fatigue, anxiety, nausea, and well-being among outpatients with cancer. The study involved 392 Reiki sessions for 268 unique patients, showing a mean improvement of 1.78 in pain and 2.09 in anxiety.

SourceUniversity Hospitals Cleveland Medical Center·JournalJournal of Pain and Symptom Management·DateDec 12, 2024

Study finds new blood test predicts prognosis for advanced prostate cancer patients

A new DNA sequencing test called AR-ctDETECT has been found to distinguish between patients with poor and favorable prognoses in advanced prostate cancer. The test identified circulating tumor DNA in 59% of patients and showed that detectable ctDNA was associated with worse overall survival.

SourceUniversity of Minnesota Medical School·JournalNature Communications·TypeRandomized controlled/clinical trial·DateDec 11, 2024

Geriatric surgery verification program can improve outcomes for older cancer patients in community hospitals

The American College of Surgeons Geriatric Surgery Verification program significantly decreases hospital stays among older cancer patients, increasing their independence and likelihood of discharge home. The program addresses the unique needs of older adults undergoing major abdominal oncologic procedures.

SourceAmerican College of Surgeons·JournalJournal of the American College of Surgeons·DateDec 10, 2024